Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 588 articles:
HTML format



Single Articles


    June 2024
  1. GARCIA MJ, Gisbert JP, Chaparro M
    Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jun 6. doi: 10.1111/apt.18104.
    PubMed    


  2. STRANDE V, Lund C, Hagen M, Bengtson MB, et al
    Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
    Aliment Pharmacol Ther. 2024 Jun 4. doi: 10.1111/apt.18097.
    PubMed     Abstract available


  3. CHETWOOD JD, Ding NS
    Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions.
    Aliment Pharmacol Ther. 2024 Jun 3. doi: 10.1111/apt.18056.
    PubMed    


  4. SONG S, Lv J, Li L, Pang Y, et al
    Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1453-1454.
    PubMed    


  5. ALIU A, Bosch DHCA, Keszthelyi D, Ardabili AR, et al
    Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1646-1647.
    PubMed    


  6. LEONG RW, Jairath V, Ma C
    Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD.
    Aliment Pharmacol Ther. 2024;59:1644-1645.
    PubMed    


  7. BEATON D, Sharp L, Lu L, Trudgill N, et al
    Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database.
    Aliment Pharmacol Ther. 2024;59:1589-1603.
    PubMed     Abstract available


    May 2024
  8. DUTT K, Vasudevan A
    Editorial: Exclusive enteral nutrition: Positioning in the ever-growing landscape of inflammatory bowel disease therapy.
    Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18055.
    PubMed    


  9. ALAHMAD M, Quraishi MN, Khan SW, Omar NM, et al
    Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18049.
    PubMed    


  10. YIU TH, Ko Y, Pudipeddi A, Natale P, et al
    Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18057.
    PubMed    


  11. VUIJK SA, de Ridder L
    Editorial: Infliximab induction therapy in paediatric Crohn's disease: A cost-effective strategy? Authors' reply.
    Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18053.
    PubMed    


  12. CHANCHLANI N, Russell RK
    Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
    Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18033.
    PubMed    


  13. PLOTKIN L, Buchuk R, Lujan R, Focht G, et al
    Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long-term nationwide study from the epi-IIRN.
    Aliment Pharmacol Ther. 2024 May 14. doi: 10.1111/apt.18028.
    PubMed     Abstract available


  14. NEDUMANNIL L, Mohamedrashed M, Bohra A, Sood S, et al
    Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:1162-1163.
    PubMed    


  15. BARTH I, Stevens CL, Strokap CJ, Campmans-Kuijpers MJE, et al
    Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualised dietary strategies.
    Aliment Pharmacol Ther. 2024;59:1154-1155.
    PubMed    


  16. THWAITES PA, Gibson PR
    Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1164-1165.
    PubMed    


  17. SEIDELIN JB
    Editorial: Time to address quality of life in our IBD treatment-IBD nurse intervention as a key part of multimodal IBD management.
    Aliment Pharmacol Ther. 2024;59:1152-1153.
    PubMed    


  18. GARCIA MJ, Gisbert JP, Chaparro M
    Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1298-1299.
    PubMed    


  19. DERIKX LAAP, Hoentjen F
    Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision?
    Aliment Pharmacol Ther. 2024;59:1296-1297.
    PubMed    


  20. SHAH A, Holtmann G
    Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?
    Aliment Pharmacol Ther. 2024;59:1290-1291.
    PubMed    


  21. NORGARD BM, Thorarinsson CT, Zegers FD, Kjeldsen J, et al
    The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study.
    Aliment Pharmacol Ther. 2024 May 1. doi: 10.1111/apt.18014.
    PubMed     Abstract available


    April 2024
  22. SONG S, Wu Z, Lv J, Yu C, et al
    Dietary factors and patterns in relation to risk of later-onset ulcerative colitis in Chinese: A prospective study of 0.5 million people.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17963.
    PubMed     Abstract available


  23. FUKUDA T, Yamazaki H, Miyatani Y, Sawada T, et al
    Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18013.
    PubMed     Abstract available


  24. YIU TH, Ko Y, Pudipeddi A, Natale P, et al
    Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18006.
    PubMed     Abstract available


  25. FERNANDEZ-CLOTET A, Ordas I, Masamunt MC, Caballol B, et al
    Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17968.
    PubMed     Abstract available


  26. VUIJK SA, Jongsma MME, Hoeven BM, Cozijnsen MA, et al
    Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000.
    PubMed     Abstract available


  27. URQUHART SA, Fletcher JG, Bruining DH
    Editorial: Foretelling the future-Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17991.
    PubMed    


  28. OKABAYASHI S, Kobayashi T
    Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia?
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17983.
    PubMed    


  29. ARATARI A, Scribano ML, Pugliese D, Baccolini V, et al
    Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate-A retrospective multicentre real-world study.
    Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.18001.
    PubMed     Abstract available


  30. KIM K, Park JJ, Yoon H, Lee J, et al
    Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
    Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.17989.
    PubMed     Abstract available


  31. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    PubMed     Abstract available


  32. VASUDEVAN A, Con D, van Langenberg DR
    Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1011.
    PubMed    


  33. ASONUMA K, Sagami S, Kobayashi T
    Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
    Aliment Pharmacol Ther. 2024;59:1005-1006.
    PubMed    


  34. CHETWOOD JD, Paramsothy S, Leong RW
    Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2024;59:1009-1010.
    PubMed    


    March 2024
  35. AKIYAMA S, Yokoyama K, Yagi S, Shinzaki S, et al
    Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961.
    PubMed     Abstract available


  36. RICCIUTO A, Liu K, El-Matary W, Amin M, et al
    Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
    Aliment Pharmacol Ther. 2024 Mar 10. doi: 10.1111/apt.17936.
    PubMed     Abstract available


  37. GARCIA MJ, Riestra S, Amiot A, Julsgaard M, et al
    Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
    Aliment Pharmacol Ther. 2024 Mar 6. doi: 10.1111/apt.17938.
    PubMed     Abstract available


  38. LU C, Rosentreter R, Delisle M, White M, et al
    Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
    Aliment Pharmacol Ther. 2024 Mar 4. doi: 10.1111/apt.17918.
    PubMed     Abstract available


  39. GONCZI L, Lakatos L, Ilias A, Lakatos PL, et al
    Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:715-716.
    PubMed    


  40. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:723-724.
    PubMed    


  41. LAHARIE D
    Letter: Should ulcerative colitis be monitored more or less invasively?
    Aliment Pharmacol Ther. 2024;59:721-722.
    PubMed    


  42. TASSONE D, Hartley I, Ding NS
    Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
    Aliment Pharmacol Ther. 2024;59:713-714.
    PubMed    


  43. VAN LIERE ELSA, de Boer NKH
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024;59:792-793.
    PubMed    


  44. VASUDEVAN A, Con D, van Langenberg DR
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2024;59:794.
    PubMed    


  45. BOKEMEYER B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, et al
    Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study).
    Aliment Pharmacol Ther. 2024 Mar 1. doi: 10.1111/apt.17926.
    PubMed     Abstract available


    February 2024
  46. ERIKSSON C, Sun J, Bryder M, Broms G, et al
    Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
    PubMed     Abstract available


  47. ZAMANI M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, et al
    Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Feb 19. doi: 10.1111/apt.17919.
    PubMed     Abstract available


  48. SAGAMI S, Kobayashi T
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
    Aliment Pharmacol Ther. 2024;59:579-580.
    PubMed    


  49. PANACCIONE R
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.
    Aliment Pharmacol Ther. 2024;59:581-582.
    PubMed    


  50. VASUDEVAN A, Con D, De Cruz P, Sparrow MP, et al
    Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
    Aliment Pharmacol Ther. 2024;59:504-514.
    PubMed     Abstract available


    January 2024
  51. CON D, Srinivasan A
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
    Aliment Pharmacol Ther. 2024;59:140-141.
    PubMed    


  52. VAN DE MEEBERG MM, Fidder HH, de Jonge R, Bouma G, et al
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:120-121.
    PubMed    


  53. BARCLAY ML, Stamp LK
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:118-119.
    PubMed    


  54. PRAY C, Narula N
    Editorial: Moving towards prognostic endoscopic scoring in IBD.
    Aliment Pharmacol Ther. 2024;59:132-133.
    PubMed    


    December 2023
  55. GONCZI L, Lakatos L, Golovics PA, Angyal D, et al
    Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades - Results from a population-based study over four decades.
    Aliment Pharmacol Ther. 2023 Dec 19. doi: 10.1111/apt.17836.
    PubMed     Abstract available


  56. MEYER A, Dong C, Chan SSM, Touvier M, et al
    Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Dec 15. doi: 10.1111/apt.17835.
    PubMed     Abstract available


  57. DESAI A, Regueiro M, Kochhar GS
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    


  58. SOHN J
    Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    


  59. REZAZADEH ARDABILI A, Janssen L, Mujagic Z
    Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    


  60. CHANG HC, Gau SY
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    


  61. BASSOTTI G, Villanacci V, Maconi G
    Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    


    November 2023
  62. BUISSON A, Nachury M, Bazoge M, Yzet C, et al
    Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17822.
    PubMed     Abstract available


  63. PEYRIN-BIROULET L, Vermeire S, D'Haens G, Panes J, et al
    Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17751.
    PubMed     Abstract available


  64. PANACCIONE R, Danese S, Zhou W, Klaff J, et al
    Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Nov 27. doi: 10.1111/apt.17816.
    PubMed     Abstract available


  65. BOKEMEYER B, Plachta-Danielzik S
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
    Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
    PubMed    


  66. KELLER JJ, Terveer EM
    Editorial: Continuous monitoring to improve outcome of treatment-the next step towards safe and effective faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2023;58:946-947.
    PubMed    


  67. DAN L, Wang X, Chen J
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD. Authors' reply.
    Aliment Pharmacol Ther. 2023;58:940-941.
    PubMed    


  68. LOPES EW, Khalili H
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD.
    Aliment Pharmacol Ther. 2023;58:938-939.
    PubMed    


    October 2023
  69. SPARTZ EJ, DeDecker LC, Fansiwala KM, Noorian S, et al
    Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Oct 24. doi: 10.1111/apt.17777.
    PubMed     Abstract available


  70. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17753.
    PubMed     Abstract available


  71. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    PubMed     Abstract available


  72. KAYAL M, Meringer H, Martin L, Colombel JF, et al
    Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
    Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
    PubMed     Abstract available


  73. RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
    Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
    Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
    PubMed     Abstract available


  74. WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
    Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
    Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
    PubMed     Abstract available


  75. TASSONE D, Hartley I, Ding NS
    Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:729-730.
    PubMed    


  76. ANDREW B, Zhou A, Trinh S, Srinivasan A, et al
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
    Aliment Pharmacol Ther. 2023;58:838-839.
    PubMed    


  77. OH SJ, Kim HJ, Lee CK
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:840-841.
    PubMed    


  78. ARULJOTHY A, Singh S, Narula N, Moran GW, et al
    Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
    Aliment Pharmacol Ther. 2023;58:740-762.
    PubMed     Abstract available


  79. REZAZADEH ARDABILI A, Van Bodegraven AA
    Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.
    Aliment Pharmacol Ther. 2023;58:832-833.
    PubMed    


    September 2023
  80. VAN DE MEEBERG MM, Fidder HH, Oldenburg B, Sundaresan J, et al
    Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719.
    PubMed     Abstract available


  81. FAQERAH N, Walker D, Gerasimidis K
    Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
    PubMed     Abstract available


  82. JANSSEN LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, et al
    Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors.
    Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17718.
    PubMed     Abstract available


  83. SCHREIBER S, Rogler G, Watanabe M, Vermeire S, et al
    Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
    Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17674.
    PubMed     Abstract available


  84. ANDREW B, Srinivasan A, Zhou A, Vasudevan A, et al
    Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted.
    Aliment Pharmacol Ther. 2023;58:556-557.
    PubMed    


  85. YAMAMOTO T
    Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:546-547.
    PubMed    


  86. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
    Aliment Pharmacol Ther. 2023;58:492-502.
    PubMed     Abstract available


  87. WU X, Yang Y
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD) - A good treatment option for active ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:640.
    PubMed    


  88. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:634-635.
    PubMed    


  89. KEDIA S, Ahuja V
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
    Aliment Pharmacol Ther. 2023;58:632-633.
    PubMed    


  90. YANAI H, Salomon N, Ben-Horin S, Kopylov U, et al
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD)-A good treatment option for active ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:641.
    PubMed    


    August 2023
  91. HONAP S, Peyrin-Biroulet L
    Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2023 Aug 21. doi: 10.1111/apt.17684.
    PubMed     Abstract available


  92. EVERHOV AH, Soderling J, Befrits G, Khalili H, et al
    Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
    Aliment Pharmacol Ther. 2023 Aug 18. doi: 10.1111/apt.17675.
    PubMed     Abstract available


  93. WOELFEL S, Dutschler J, Konig M, Dulovic A, et al
    STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Aug 12. doi: 10.1111/apt.17661.
    PubMed     Abstract available


  94. LOBATON T, Truyens M
    Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:359-360.
    PubMed    


  95. KANE S
    Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBD.
    Aliment Pharmacol Ther. 2023;58:357-358.
    PubMed    


  96. KIRCHGESNER J, Beaugerie L
    Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:363.
    PubMed    


  97. TASSONE D, Hartley I, Ding NS
    Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:376-377.
    PubMed    


  98. VELAYOS FS
    Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?
    Aliment Pharmacol Ther. 2023;58:361-362.
    PubMed    


    July 2023
  99. DENG M, Dan L, Ye S, Chen X, et al
    Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study.
    Aliment Pharmacol Ther. 2023 Jul 18. doi: 10.1111/apt.17649.
    PubMed     Abstract available


  100. MIN Y, Wei X, Peng X
    Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
    Aliment Pharmacol Ther. 2023;58:143-144.
    PubMed    


  101. MASSIRONI S, Vigano C, Danese S
    Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:145-146.
    PubMed    


  102. MILES M, Nasser Y
    Editorial: faecal incontinence in ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58:114-115.
    PubMed    


  103. CHAN P, Connor S, Huang V, Karimi N, et al
    Letter: expanding the role for decision aids in IBD into pregnancy-related topics.
    Aliment Pharmacol Ther. 2023;58:141-142.
    PubMed    


  104. ESTEVINHO MM, Magro F
    Editorial: elderly onset inflammatory bowel disease - clues from the largest population-based cohort study.
    Aliment Pharmacol Ther. 2023;58:116-117.
    PubMed    


  105. HUDSON AS, Huynh HQ
    Editorial: Predicting paediatric ulcerative colitis outcomes-how can we improve?
    Aliment Pharmacol Ther. 2023;58:258-259.
    PubMed    


  106. OH SJ, Kim HJ, Lee CK
    Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:256-257.
    PubMed    


  107. EBRAHIMI F, Forss A
    Editorial: Antibiotics and risk of IBD-Can we close the books?
    Aliment Pharmacol Ther. 2023;58:254-255.
    PubMed    


  108. BACSUR P, Ilias A, Resal T, Kata D, et al
    Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
    Aliment Pharmacol Ther. 2023;58:262-263.
    PubMed    


    June 2023
  109. D'HAENS G, Peyrin-Biroulet L, Marks DJB, Lisi E, et al
    A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17557.
    PubMed     Abstract available


  110. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
    Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study.
    Aliment Pharmacol Ther. 2023 Jun 15. doi: 10.1111/apt.17616.
    PubMed     Abstract available


  111. NGUYEN AL, Burns M, Herath M, Lambell K, et al
    Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jun 12. doi: 10.1111/apt.17607.
    PubMed     Abstract available


  112. KOCHHAR GS, Desai A, Farraye FA, Cross RK, et al
    Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
    Aliment Pharmacol Ther. 2023 Jun 9. doi: 10.1111/apt.17570.
    PubMed     Abstract available


  113. MACALUSO FS, Orlando A
    Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
    Aliment Pharmacol Ther. 2023;57:1343-1344.
    PubMed    


  114. CALDERA F, Spaulding AC, Hayney MS, Farraye FA, et al
    Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1345-1346.
    PubMed    


  115. CHEN P, Chen F
    Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
    Aliment Pharmacol Ther. 2023;57:1349-1350.
    PubMed    


  116. IKEGAMI S, Nakamura M, Honda T, Kawashima H, et al
    Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1351-1352.
    PubMed    


  117. HANZEL J, Drobne D
    Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
    Aliment Pharmacol Ther. 2023;57:1469-1470.
    PubMed    


  118. SETHI S, Kumar A, Dias S, Blackwell J, et al
    Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1455-1456.
    PubMed    


  119. FUMERY M, Roblin X
    Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
    Aliment Pharmacol Ther. 2023;57:1471-1472.
    PubMed    


  120. ROBLIN X, Nancey S
    Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
    Aliment Pharmacol Ther. 2023;57:1453-1454.
    PubMed    


  121. POLLOK RC, Jayasooriya N, Baillie S, Blackwell J, et al
    Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1479.
    PubMed    


  122. CHANG HC, Gau SY
    Letter: histologic disease activity and colorectal neoplasia risk.
    Aliment Pharmacol Ther. 2023;57:1480.
    PubMed    


  123. LUCAS S, Chauhan A, Garg M
    Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach.
    Aliment Pharmacol Ther. 2023;57:1477-1478.
    PubMed    


    May 2023
  124. ATIA O, Klomberg RCW, de Ridder L, Kemos P, et al
    Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
    Aliment Pharmacol Ther. 2023 May 29. doi: 10.1111/apt.17544.
    PubMed     Abstract available


  125. KREIJNE JE, Goetgebuer RL, Erler NS, De Boer NK, et al
    Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 May 23. doi: 10.1111/apt.17555.
    PubMed     Abstract available


  126. YANAI H, Salomon N, Lahat A, Ungar B, et al
    Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
    Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17538.
    PubMed     Abstract available


  127. OH SJ, Kim HJ, Lee CK
    A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea.
    Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17542.
    PubMed     Abstract available


  128. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
    Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1034-1035.
    PubMed    


  129. VAN RULER O, Arkenbosch JHC, van der Woude CJ
    Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1030-1031.
    PubMed    


  130. BURISCH J
    Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
    Aliment Pharmacol Ther. 2023;57:1044-1045.
    PubMed    


  131. DART RJ
    Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
    Aliment Pharmacol Ther. 2023;57:1028-1029.
    PubMed    


  132. MEYER A, Amiot A, Carbonnel F
    Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
    Aliment Pharmacol Ther. 2023;57:1032-1033.
    PubMed    


  133. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
    Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1048-1049.
    PubMed    


  134. GEERTSEMA S, van Goor H, Dijkstra G, Faber KN, et al
    Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
    Aliment Pharmacol Ther. 2023;57:1046-1047.
    PubMed    


  135. SONNENBERG A, Genta RM
    Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1155-1156.
    PubMed    


  136. SZIGETI R, Krishna M, Kellermayer R
    Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype?
    Aliment Pharmacol Ther. 2023;57:1192-1193.
    PubMed    


  137. POLLOK RC, Baillie S, Jayasooriya N, Blackwell J, et al
    Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1205-1206.
    PubMed    


  138. ATIA O, Goren I, Yanai H
    Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1184-1185.
    PubMed    


  139. ANDERSON RP
    Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter?
    Aliment Pharmacol Ther. 2023;57:1153-1154.
    PubMed    


  140. TASSONE D, Gilmore R, Lee T, Ding NS, et al
    Letter: diagnostic delay in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:1203-1204.
    PubMed    


  141. JAYASOORIYA N, Saxena S, Pollok RC
    Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1194-1195.
    PubMed    


  142. CHANG HC, Gau SY
    Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease.
    Aliment Pharmacol Ther. 2023;57:1183.
    PubMed    


    April 2023
  143. CASANOVA MJ, Nantes O, Varela P, Vela-Gonzalez M, et al
    Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Aliment Pharmacol Ther. 2023 Apr 23. doi: 10.1111/apt.17525.
    PubMed     Abstract available


  144. NORGARD BM, Zegers FD, Knudsen T, Kjeldsen J, et al
    Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17520.
    PubMed     Abstract available


  145. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Helwig U, et al
    Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
    Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17512.
    PubMed     Abstract available


  146. GOLD SL, Raman M, Sands BE, Ungaro R, et al
    Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17498.
    PubMed     Abstract available


  147. OLIVERA PA, Lasa JS, Peretto G, Zuily S, et al
    Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
    Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17509.
    PubMed     Abstract available


  148. VASANT DH, Nigam GB, Bate S, Hamdy S, et al
    The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
    Aliment Pharmacol Ther. 2023 Apr 3. doi: 10.1111/apt.17502.
    PubMed     Abstract available


  149. GUPTA A, Kedia S, Ahuja V
    Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
    Aliment Pharmacol Ther. 2023;57:815-816.
    PubMed    


  150. SPEEDY AP, Wall CL
    Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:907-908.
    PubMed    


    March 2023
  151. WOLF T, Lewis A, Beaugerie L, Svrcek M, et al
    Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps.
    Aliment Pharmacol Ther. 2023 Mar 31. doi: 10.1111/apt.17495.
    PubMed     Abstract available


  152. CALDERA F, Spaulding AC, Borah B, Moriarty J, et al
    Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Mar 10. doi: 10.1111/apt.17454.
    PubMed     Abstract available


  153. ATIA O, Goren I, Fischler TS, Weisband YL, et al
    5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
    Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17419.
    PubMed     Abstract available


  154. MELTON SL, Taylor KM, Gibson PR, Halmos EP, et al
    Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
    Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17451.
    PubMed     Abstract available


  155. CHANG HC, Gau SY
    Letter: sleep duration and the incidence of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:595-596.
    PubMed    


  156. COLMAN RJ, Minar P
    Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2023;57:567-568.
    PubMed    


  157. HORSFALL E, Irwin J
    Editorial: inflammatory bowel disease and sleep.
    Aliment Pharmacol Ther. 2023;57:573-574.
    PubMed    


  158. CORTESI PA, Fiorino G, Mantovani LG, Danese S, et al
    Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:571-572.
    PubMed    


  159. BARBER GE, Gubatan J
    Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay?
    Aliment Pharmacol Ther. 2023;57:569-570.
    PubMed    


  160. YUAN S, Chen J, Li X
    Editorial: IBD and sleep-authors' reply.
    Aliment Pharmacol Ther. 2023;57:575-576.
    PubMed    


  161. VUIJK SA, de Ridder L
    Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:565-566.
    PubMed    


  162. PEYRIN-BIROULET L, Ghosh S, Lee SD, Lee WJ, et al
    Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
    Aliment Pharmacol Ther. 2023;57:496-508.
    PubMed     Abstract available


  163. BUISSON A
    Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:735-736.
    PubMed    


  164. VOLKERS A, Straatmijer T, Duijvestein M, Lowenberg M, et al
    Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.
    Aliment Pharmacol Ther. 2023;57:743-744.
    PubMed    


  165. ERNEST-SUAREZ K, Lu C
    Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?
    Aliment Pharmacol Ther. 2023;57:733-734.
    PubMed    


  166. RICHARD N, Vuitton L, Fumery M
    Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:741-742.
    PubMed    


    February 2023
  167. FUMERY M, Nancey S, Filippi J, Altwegg R, et al
    Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
    Aliment Pharmacol Ther. 2023 Feb 27. doi: 10.1111/apt.17421.
    PubMed     Abstract available


  168. REGEV S, Schwartz D, Sarid O, Goren G, et al
    Randomised clinical trial: Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease.
    Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17399.
    PubMed     Abstract available


  169. SONNENBERG A, Genta RM
    Case-control study of the concurrence of coeliac disease with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17408.
    PubMed     Abstract available


  170. CHOWDHURY R, Kane SV
    Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
    Aliment Pharmacol Ther. 2023;57:349-350.
    PubMed    


  171. VESTERGAARD T, Kelsen J, Julsgaard M
    Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease - a Danish cohort study. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:351-352.
    PubMed    


    January 2023
  172. CHEN J, Ruan X, Yuan S, Deng M, et al
    Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17392.
    PubMed     Abstract available


  173. TAXONERA C, Olivares D, Lopez-Garcia ON, Alba C, et al
    Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17386.
    PubMed     Abstract available


  174. KHAN N, Mahmud N, Patel M, Sundararajan R, et al
    Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17393.
    PubMed     Abstract available


  175. IKEGAMI S, Nakamura M, Honda T, Yamamura T, et al
    Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study.
    Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17387.
    PubMed     Abstract available


  176. DUA A, Corson M, Sauk JS, Jaffe N, et al
    Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jan 13. doi: 10.1111/apt.17389.
    PubMed     Abstract available


  177. JAYASOORIYA N, Baillie S, Blackwell J, Bottle A, et al
    Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jan 10. doi: 10.1111/apt.17370.
    PubMed     Abstract available


  178. LAHARIE D, Riviere P
    Editorial: selecting therapy for ulcerative colitis-think a step ahead.
    Aliment Pharmacol Ther. 2023;57:161-162.
    PubMed    


  179. WOELFEL S, Dutschler J, Konig M, Graf N, et al
    Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Aliment Pharmacol Ther. 2023;57:103-116.
    PubMed     Abstract available


  180. REIJNTJES MA, de Voogd FAE, Buskens CJ, Gecse KB, et al
    Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:255-256.
    PubMed    


  181. SCRIBANO ML
    Editorial: shared decision-making intervention in patients with Crohn's disease-a personalised, patient-centred approach.
    Aliment Pharmacol Ther. 2023;57:263-264.
    PubMed    


  182. ERNEST-SUAREZ K, Novak K
    Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix?
    Aliment Pharmacol Ther. 2023;57:253-254.
    PubMed    


  183. LIWINSKI T, Hubener S, Henze L, Hubener P, et al
    A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
    Aliment Pharmacol Ther. 2023;57:224-236.
    PubMed     Abstract available


    December 2022
  184. DIN S, Selinger CP, Black CJ, Ford AC, et al
    Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Dec 31. doi: 10.1111/apt.17379.
    PubMed     Abstract available


  185. ARKENBOSCH JHC, van Ruler O, Dwarkasing RS, Fuhler GM, et al
    Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study.
    Aliment Pharmacol Ther. 2022 Dec 26. doi: 10.1111/apt.17347.
    PubMed     Abstract available


  186. FUMERY M, Defrance A, Roblin X, Altwegg R, et al
    Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Dec 19. doi: 10.1111/apt.17358.
    PubMed     Abstract available


  187. VESTERGAARD T, Julsgaard M, Rosok JF, Vestergaard SV, et al
    Predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
    Aliment Pharmacol Ther. 2022 Dec 14. doi: 10.1111/apt.17348.
    PubMed     Abstract available


  188. SETHI S, Dias S, Kumar A, Blackwell J, et al
    Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Dec 9. doi: 10.1111/apt.17313.
    PubMed     Abstract available


  189. VUIJK SA, de Ridder L
    Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    


  190. KULYK A, Shafer LA, Graff LA, Stone J, et al
    Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study).
    Aliment Pharmacol Ther. 2022;56.
    PubMed     Abstract available


    November 2022
  191. BUISSON A, Nachury M, Guilmoteau T, Altwegg R, et al
    Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Aliment Pharmacol Ther. 2022 Nov 19. doi: 10.1111/apt.17305.
    PubMed     Abstract available


  192. CORTESI PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, et al
    Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17261.
    PubMed     Abstract available


  193. ZISMAN-ILANI Y, Thompson KD, Siegel LS, Mackenzie T, et al
    Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
    Aliment Pharmacol Ther. 2022 Nov 14. doi: 10.1111/apt.17286.
    PubMed     Abstract available


  194. YUAN S, Sun Y, Tan X, Geng J, et al
    Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285.
    PubMed     Abstract available


  195. EVERHOV AH, Olen O
    Editorial: colorectal cancer in elderly-onset IBD-what is the risk? Authors' reply.
    Aliment Pharmacol Ther. 2022;56:1423-1424.
    PubMed    


  196. WEISS A, Buchner AM
    Editorial: colorectal cancer in elderly-onset inflammatory bowel disease-what is the risk?
    Aliment Pharmacol Ther. 2022;56:1421-1422.
    PubMed    


  197. LEE KE, Faye AS
    Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:1427-1428.
    PubMed    


  198. SAHYOUN L, Dahiya DS, Cheng CI, Sultan K, et al
    Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism.
    Aliment Pharmacol Ther. 2022;56:1425-1426.
    PubMed    


  199. BEZZIO C, Alimenti E, Saibeni S
    Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution?
    Aliment Pharmacol Ther. 2022;56:1429-1430.
    PubMed    


  200. DAHL EK, Abed OK, Kjeldsen J, Donia M, et al
    Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
    Aliment Pharmacol Ther. 2022;56:1370-1382.
    PubMed     Abstract available


  201. NORGARD BM, Friedman S, Kjeldsen J, Nielsen J, et al
    The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
    Aliment Pharmacol Ther. 2022;56:1349-1360.
    PubMed     Abstract available


  202. RONNOW SAND J, Troelsen FS, Horvath-Puho E, Henderson VW, et al
    Letter: comedication use and dementia risk in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1505-1506.
    PubMed    


  203. CHANG HC, Gau SY
    Letter: comedication use and dementia risk in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1503-1504.
    PubMed    


  204. REIJNTJES MA, de Voogd FAE, Bemelman WA, Hompes R, et al
    Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 1. doi: 10.1111/apt.17267.
    PubMed     Abstract available


    October 2022
  205. COLMAN RJ, Mizuno T, Fukushima K, Haslam DB, et al
    Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
    Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17277.
    PubMed     Abstract available


  206. STRAATMIJER T, van Schaik FDM, Bodelier AGL, Visschedijk M, et al
    Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
    Aliment Pharmacol Ther. 2022 Oct 25. doi: 10.1111/apt.17248.
    PubMed     Abstract available


  207. SAIFUDDIN A, Kent AJ, Mehta SJ, Hicks LC, et al
    Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Oct 5. doi: 10.1111/apt.17223.
    PubMed     Abstract available


  208. BURGESS CJ, Jackson R, Chalmers I, Russell RK, et al
    The inexorable increase of biological exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
    Aliment Pharmacol Ther. 2022 Oct 4. doi: 10.1111/apt.17217.
    PubMed     Abstract available


  209. BURISCH J
    Editorial: trends in the epidemiology of inflammatory bowel disease in Korea.
    Aliment Pharmacol Ther. 2022;56:1207-1208.
    PubMed    


  210. BODGER K
    Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2022;56:1211-1212.
    PubMed    


  211. SHIM JO
    Editorial: trends in the epidemiology of inflammatory bowel disease in Korea - author's reply.
    Aliment Pharmacol Ther. 2022;56:1209-1210.
    PubMed    


  212. LEE KE, Faye AS
    Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1213-1214.
    PubMed    


  213. CHOI SY, Kim ES, Jeon TY, Lee YM, et al
    Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics.
    Aliment Pharmacol Ther. 2022;56:1146-1156.
    PubMed     Abstract available


  214. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    PubMed    


  215. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    PubMed    


    September 2022
  216. AVNI-BIRON I, Mishael T, Zittan E, Livne-Margolin M, et al
    Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Sep 27. doi: 10.1111/apt.17224.
    PubMed     Abstract available


  217. BLACK J, Sweeney L, Yuan Y, Singh H, et al
    Systematic review: the role of psychological stress in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Sep 8. doi: 10.1111/apt.17202.
    PubMed     Abstract available


  218. ROSIOU K, Selinger CP
    Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:898-899.
    PubMed    


  219. HAYDEK JP, Scott FI
    Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
    Aliment Pharmacol Ther. 2022;56:896-897.
    PubMed    


  220. BERTANI L, Trico D
    Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue.
    Aliment Pharmacol Ther. 2022;56:903-904.
    PubMed    


  221. HUDSON AS, Wine E
    Editorial: further support for exclusive enteral nutrition in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:900-901.
    PubMed    


  222. KANE S
    Editorial: paternal use of IBD therapies and risk of infant infection.
    Aliment Pharmacol Ther. 2022;56:902.
    PubMed    


  223. LIN S, Chanchlani N, Carbery I, Janjua M, et al
    Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naive patients with active luminal Crohn's disease?
    Aliment Pharmacol Ther. 2022;56:783-793.
    PubMed     Abstract available


  224. ATIA O, Pujol-Muncunill G, Navas-Lopez VM, Orlanski-Meyer E, et al
    Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.
    Aliment Pharmacol Ther. 2022;56:794-801.
    PubMed     Abstract available


  225. LIMA CCG, Peerani F
    Editorial: IBD and the risk of dementia - the jury is still out.
    Aliment Pharmacol Ther. 2022;56:1078-1079.
    PubMed    


  226. LOPES EW, Khalili H
    Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1086-1087.
    PubMed    


  227. FU T, Wang X, Chen J
    Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1088-1089.
    PubMed    


  228. HENDERSON P
    Editorial: earning potential in paediatric-onset IBD-a complex interplay.
    Aliment Pharmacol Ther. 2022;56:1084-1085.
    PubMed    


  229. ZHAO M, Lirhus S, Lordal M, Langholz E, et al
    Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
    Aliment Pharmacol Ther. 2022;56:989-1006.
    PubMed     Abstract available


  230. VOLKERS A, Straatmijer T, Duijvestein M, Sales A, et al
    Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;56:1044-1054.
    PubMed     Abstract available


    August 2022
  231. CHANCHLANI N, Lin S, Auth MK, Lee CL, et al
    Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Aliment Pharmacol Ther. 2022 Aug 29. doi: 10.1111/apt.17170.
    PubMed     Abstract available


  232. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    PubMed     Abstract available


  233. IRVING PM, Leung Y, Dubinsky MC
    Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17185.
    PubMed     Abstract available


  234. MALMBORG P, Everhov AH, Soderling J, Ludvigsson JF, et al
    Earnings during adulthood in patients with childhood-onset inflammatory bowel disease: A nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17148.
    PubMed     Abstract available


  235. EVERHOV AH, Erichsen R, Jaras J, Pedersen L, et al
    Colorectal cancer in elderly-onset inflammatory bowel disease: A 1969-2017 Scandinavian register-based cohort study.
    Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17175.
    PubMed     Abstract available


  236. SOHOULI MH, Fatahi S, Farahmand F, Alimadadi H, et al
    Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:384-395.
    PubMed     Abstract available


  237. TAXONERA C
    Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis-Author's reply.
    Aliment Pharmacol Ther. 2022;56:737-738.
    PubMed    


  238. HAWTHORNE AB, Lamb CA
    Editorial: quality assessment in IBD in high resource countries can lead to quality improvement clues for IBD management worldwide-authors' reply.
    Aliment Pharmacol Ther. 2022;56:743.
    PubMed    


  239. MANTZARIS GJ, Papamichael K
    Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022;56:735-736.
    PubMed    


  240. PUGLIESE D, Privitera G, Armuzzi A
    Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:733-734.
    PubMed    


  241. BERNSTEIN CN
    Editorial: quality assessment in IBD in high-resource countries can lead to quality improvement clues for IBD management worldwide.
    Aliment Pharmacol Ther. 2022;56:741-742.
    PubMed    


  242. KEEFER L, Shapiro MJ
    Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts.
    Aliment Pharmacol Ther. 2022;56:744-745.
    PubMed    


  243. LEE H, Khan N
    Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.
    Aliment Pharmacol Ther. 2022;56:731-732.
    PubMed    


  244. GOLD SL, Raman M
    Editorial: a formula shake each day keeps the complications away - the tolerability and effect of orally-delivered enteral nutrition in improving post-operative outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:739-740.
    PubMed    


  245. SWAMINATHAN A, Mules TC, Gearry RB
    Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:746-747.
    PubMed    


  246. MEADE S, Patel KV, Luber RP, O'Hanlon D, et al
    A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre.
    Aliment Pharmacol Ther. 2022;56:646-663.
    PubMed     Abstract available


  247. BOURGONJE AR, Alexdottir MS, Otten AT, Loveikyte R, et al
    Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:675-693.
    PubMed     Abstract available


    July 2022
  248. FAYE AS, Lee KE, Dodson J, Chodosh J, et al
    Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.
    Aliment Pharmacol Ther. 2022 Jul 25. doi: 10.1111/apt.17162.
    PubMed     Abstract available


  249. FU T, Chen H, Chen X, Sun Y, et al
    Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants.
    Aliment Pharmacol Ther. 2022 Jul 18. doi: 10.1111/apt.17149.
    PubMed     Abstract available


  250. REZAZADEH ARDABILI A, Jeuring S, Mujagic Z, Oostenbrug L, et al
    Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17128.
    PubMed     Abstract available


  251. CHOE YJ, Han K, Shim JO
    Treatment patterns of anti-tumour necrosis factor-alpha and prognosis of paediatric and adult-onset inflammatory bowel disease in Korea: a nationwide population-based study.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17125.
    PubMed     Abstract available


  252. BIRON A, Beaugerie L, Chazouilleres O, Kirchgesner J, et al
    Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Jul 4. doi: 10.1111/apt.17123.
    PubMed     Abstract available


  253. SAND JR, Troelsen FS, Horvath-Puho E, Henderson VW, et al
    Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study.
    Aliment Pharmacol Ther. 2022 Jul 3. doi: 10.1111/apt.17119.
    PubMed     Abstract available


  254. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Letter: normalizing the ileoanal pouch-more than a one-step technique. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:176-177.
    PubMed    


  255. WEST J, Card TR, Crooks CJ
    Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
    Aliment Pharmacol Ther. 2022;56:157.
    PubMed    


  256. HADI Y, Kochhar GS
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
    Aliment Pharmacol Ther. 2022;56:178.
    PubMed    


  257. LO SW, Garg M, Segal JP
    Letter: normalising the ileoanal pouch-more than a one-step technique.
    Aliment Pharmacol Ther. 2022;56:174-175.
    PubMed    


  258. BHURWAL A, Mutneja H, Seril D
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:164-165.
    PubMed    


  259. BENCHIMOL EI, Kuenzig ME
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.
    Aliment Pharmacol Ther. 2022;56:162-163.
    PubMed    


  260. HADI Y, Kochhar GS
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:179.
    PubMed    


  261. FEHILY SR, Al-Ani AH, Abdelmalak J, Rentch C, et al
    Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
    Aliment Pharmacol Ther. 2022;56:6-27.
    PubMed     Abstract available


  262. VAUGHAN R, Tjandra D, Patwardhan A, Mingos N, et al
    Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:84-94.
    PubMed     Abstract available


  263. LYONS M, Derikx LAAP, Fulforth J, McCall S, et al
    Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
    Aliment Pharmacol Ther. 2022;56:67-76.
    PubMed     Abstract available


  264. ROBLIN X, Veyrard P, Bastide L, Berger AE, et al
    Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:77-83.
    PubMed     Abstract available


  265. MASSIRONI S, Vigano C, Danese S
    Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:371.
    PubMed    


  266. DAI C, Huang YH
    Letter: pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:370.
    PubMed    


  267. SOLITANO V, Armuzzi A
    Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine?
    Aliment Pharmacol Ther. 2022;56:347-348.
    PubMed    


  268. FRIEDMAN S
    Editorial: measuring fertility in men with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:345-346.
    PubMed    


  269. GILL M, Majumdar A
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game.
    Aliment Pharmacol Ther. 2022;56:353-354.
    PubMed    


  270. KO KL, Hung IF, Leung WK
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:355-356.
    PubMed    


  271. MADSEN GR, Wilkens R, Boysen T, Burisch J, et al
    The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.
    Aliment Pharmacol Ther. 2022;56:263-270.
    PubMed     Abstract available


  272. PUGLIESE D, Privitera G, Crispino F, Mezzina N, et al
    Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
    Aliment Pharmacol Ther. 2022;56:95-109.
    PubMed     Abstract available


    June 2022
  273. UMAR N, King D, Chandan JS, Bhala N, et al
    The association between inflammatory bowel disease and mental ill health: A retrospective cohort study using data from UK primary care.
    Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17110.
    PubMed     Abstract available


  274. FRIEDMAN S, Garvik OS, Nielsen J, Norgard BM, et al
    Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: A nationwide cohort study.
    Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17113.
    PubMed     Abstract available


  275. YUAN WQ, Li F, Yang LC, Yang ZL, et al
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1464-1465.
    PubMed    


  276. WANG CY, Lai CC
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1462-1463.
    PubMed    


  277. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
    Aliment Pharmacol Ther. 2022;55:1560-1568.
    PubMed     Abstract available


  278. HAWTHORNE AB, Glatter J, Blackwell J, Ainley R, et al
    Inflammatory bowel disease patient-reported quality assessment should drive service improvement: A national survey of UK IBD units and patients.
    Aliment Pharmacol Ther. 2022 Jun 1. doi: 10.1111/apt.17042.
    PubMed     Abstract available


    May 2022
  279. SWAMINATHAN A, Fan D, Borichevsky GM, Mules TC, et al
    The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17058.
    PubMed     Abstract available


  280. ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
    Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
    Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
    PubMed     Abstract available


  281. DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
    Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
    Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
    PubMed     Abstract available


  282. KO KL, Lam YF, Cheung KS, Hung IF, et al
    Clinical trial: intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2022 May 11. doi: 10.1111/apt.16970.
    PubMed     Abstract available


  283. TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
    Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
    PubMed     Abstract available


  284. MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
    Systematic review-Pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
    PubMed     Abstract available


  285. FALLOON K, Cohen B, Rieder F
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1208-1209.
    PubMed    


  286. HADI Y, Kochhar GS
    Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1228-1229.
    PubMed    


  287. KOKKOTIS G, Kitsou K, Bamias G
    Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1235-1236.
    PubMed    


  288. ARDALAN ZS, Friedman AB
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment.
    Aliment Pharmacol Ther. 2022;55:1202-1203.
    PubMed    


  289. GUILLO L, Peyrin-Biroulet L, Danese S
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1206-1207.
    PubMed    


  290. BURISCH J, Langholz E, Munkholm P
    Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1239-1240.
    PubMed    


  291. CHEN HY, Wang SI, Chang R, Wei JC, et al
    Letter: association between COVID-19 and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1226-1227.
    PubMed    


  292. DEMARZO MG, Viola A, Picci A, Fries W, et al
    Letter: the clinical course of Crohn's disease-the Sicilian experience.
    Aliment Pharmacol Ther. 2022;55:1237-1238.
    PubMed    


  293. SAGAMI S, Kobayashi T
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1204-1205.
    PubMed    


  294. BACHOUR SP, Shah RS, Lyu R, Rieder F, et al
    Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions.
    Aliment Pharmacol Ther. 2022;55:1139-1150.
    PubMed     Abstract available


  295. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1151-1159.
    PubMed     Abstract available


  296. WANG J, Goren I, Rieder F
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1360.
    PubMed    


  297. FERNANDES RG, Radford-Smith G
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?
    Aliment Pharmacol Ther. 2022;55:1350-1351.
    PubMed    


  298. RADEKE HH, Stein J
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1359.
    PubMed    


  299. OKABAYASHI S, Yamazaki H, Matsuoka K, Yamamoto Y, et al
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1352-1353.
    PubMed    


  300. KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1348-1349.
    PubMed    


  301. LOVATT J, Selinger CP
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
    Aliment Pharmacol Ther. 2022;55:1346-1347.
    PubMed    


    April 2022
  302. VERSTOCKT B, Volk V, Jaeckel C, Alsoud D, et al
    Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Apr 28. doi: 10.1111/apt.16955.
    PubMed     Abstract available


  303. VANDE CASTEELE N, Sandborn WJ, Feagan BG, Vermeire S, et al
    Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
    Aliment Pharmacol Ther. 2022 Apr 27. doi: 10.1111/apt.16937.
    PubMed     Abstract available


  304. BERGQVIST V, Holmgren J, Klintman D, Marsal J, et al
    Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Apr 25. doi: 10.1111/apt.16927.
    PubMed     Abstract available


  305. HALFVARSON JF, Ludvigsson JF, Bresso F, Askling J, et al
    Age determines the risk of familial inflammatory bowel disease-A nationwide study.
    Aliment Pharmacol Ther. 2022 Apr 22. doi: 10.1111/apt.16938.
    PubMed     Abstract available


  306. MOENS A, Sadat Seyed Tabib N, Ballet V, Sabino J, et al
    Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre.
    Aliment Pharmacol Ther. 2022 Apr 20. doi: 10.1111/apt.16928.
    PubMed     Abstract available


  307. KHALILI H, Casey K
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Aliment Pharmacol Ther. 2022;55:884.
    PubMed    


  308. YIN JQ, Wang BQ, Chen ZB, He HD, et al
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
    Aliment Pharmacol Ther. 2022;55:882-883.
    PubMed    


  309. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Letter: inflammatory bowel disease services during the Covid-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1063.
    PubMed    


  310. DEPUTY M, Hart A, Faiz O
    Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
    Aliment Pharmacol Ther. 2022;55:1064.
    PubMed    


  311. SELINGER CP, Lenti MV, De Silvestri A
    Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1070-1071.
    PubMed    


  312. ADOMI M, Ray A
    Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1069.
    PubMed    


  313. KIM ES, Choi S, Choi SY, Park JH, et al
    NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Aliment Pharmacol Ther. 2022;55:1008-1015.
    PubMed     Abstract available


  314. ALSOUD D, Verstockt B, Vermeire S
    Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
    Aliment Pharmacol Ther. 2022;55:885-886.
    PubMed    


  315. YANG H, Li B, Guo Q, Tang J, et al
    Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;55:764-777.
    PubMed     Abstract available


  316. LENTI MV, Dolby V, Clark T, Hall V, et al
    A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
    Aliment Pharmacol Ther. 2022;55:856-866.
    PubMed     Abstract available


    March 2022
  317. BHURWAL A, Mutneja H, Bansal V, Goel A, et al
    Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression.
    Aliment Pharmacol Ther. 2022 Mar 30. doi: 10.1111/apt.16913.
    PubMed     Abstract available


  318. TOWNSEND CM, Lovegrove F, Khanna R, Wilson AS, et al
    Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 21. doi: 10.1111/apt.16883.
    PubMed     Abstract available


  319. ZAMANI M, Alizadeh-Tabari S, Singh S, Loomba R, et al
    Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.
    PubMed     Abstract available


  320. OKABAYASHI S, Yamazaki H, Tominaga K, Miura M, et al
    Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16865.
    PubMed     Abstract available


  321. FALLOON K, Cohen B, Ananthakrishnan AN, Barnes EL, et al
    A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16853.
    PubMed     Abstract available


  322. SINGH AK, Jena A, Mahajan G, Mohindra R, et al
    Meta-analysis: Hepatitis B vaccination in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16880.
    PubMed     Abstract available


  323. SUNG KY, Zhang B, Wang HE, Bai YM, et al
    Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16856.
    PubMed     Abstract available


  324. PANACCIONE R, Abreu MT, Lazariciu I, Mundayat R, et al
    Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.
    Aliment Pharmacol Ther. 2022 Mar 5. doi: 10.1111/apt.16848.
    PubMed    


  325. JAYASOORIYA N, Blackwell J, Saxena S, Bottle A, et al
    Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
    Aliment Pharmacol Ther. 2022 Mar 4. doi: 10.1111/apt.16820.
    PubMed     Abstract available


  326. SAVELKOUL EHJ, Hoentjen F
    Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all.
    Aliment Pharmacol Ther. 2022;55:750-751.
    PubMed    


  327. HONAP S, Dart RJ, Samaan MA
    Editorial: protecting hypoxia-inducible factor-1alpha and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
    Aliment Pharmacol Ther. 2022;55:733-734.
    PubMed    


  328. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:735-736.
    PubMed    


  329. KUMAR P, Vuyyuru SK, Kante B, Sahu P, et al
    Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Aliment Pharmacol Ther. 2022 Mar 1. doi: 10.1111/apt.16839.
    PubMed     Abstract available


  330. ZHAO M, Sall Jensen M, Knudsen T, Kelsen J, et al
    Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.
    Aliment Pharmacol Ther. 2022;55:541-557.
    PubMed     Abstract available


  331. COLMAN RJ, Xiong Y, Mizuno T, Hyams JS, et al
    Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:593-603.
    PubMed     Abstract available


  332. COHEN NA, Pekow J
    Editorial: time to modify practice and use the modified Rutgeert's score.
    Aliment Pharmacol Ther. 2022;55:754-755.
    PubMed    


  333. BANERJEE R, Raghunathan N
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
    Aliment Pharmacol Ther. 2022;55:740-741.
    PubMed    


  334. KIM ES, Kang B
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:742-743.
    PubMed    


    February 2022
  335. BALLESTER MP, Mesonero F, Florez-Diez P, Gomez C, et al
    Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study.
    Aliment Pharmacol Ther. 2022 Feb 27. doi: 10.1111/apt.16832.
    PubMed     Abstract available


  336. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Feb 25. doi: 10.1111/apt.16817.
    PubMed     Abstract available


  337. YE Z, Qian L, Hu W, Miao S, et al
    Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
    Aliment Pharmacol Ther. 2022 Feb 20. doi: 10.1111/apt.16837.
    PubMed     Abstract available


  338. GROSSBERG LB, Papamichael K, Cheifetz AS
    Review: emerging drug therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16785.
    PubMed     Abstract available


  339. WAN J, Wang X, Zhang Y, Chen M, et al
    Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16789.
    PubMed     Abstract available


  340. DEPUTY M, Sahnan K, Worley G, Patel K, et al
    The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16800.
    PubMed     Abstract available


  341. SCHREIBER S, Irving PM, Sharara AI, Martin-Arranz MD, et al
    Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16781.
    PubMed     Abstract available


  342. POLLOK RCG, Jayasooriya N
    Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:370-371.
    PubMed    


  343. TAXONERA C
    Editorial: real-world safety of tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:368-369.
    PubMed    


  344. MAHMOUD R, Schultheiss JPD, Fidder HH, Oldenburg B, et al
    Letter: loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:499-500.
    PubMed    


  345. BEN-HORIN S, Ungar B
    Letter: loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease depends on treatment duration.
    Aliment Pharmacol Ther. 2022;55:497-498.
    PubMed    


  346. GOODSALL TM, Bryant RV
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US.
    Aliment Pharmacol Ther. 2022;55:360-361.
    PubMed    


  347. ALLOCCA M, Danese S
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:362-363.
    PubMed    


  348. ALLOCCA M, Craviotto V, Dell'Avalle C, Furfaro F, et al
    Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:446-454.
    PubMed     Abstract available


  349. SKEJO C, Vestergaard T, Julsgaard M
    Editorial: safety of ustekinumab in pregnancy-are we there yet?
    Aliment Pharmacol Ther. 2022;55:495-496.
    PubMed    


  350. CARON B, Fumery M, Netter P, Peyrin-Biroulet L, et al
    Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
    Aliment Pharmacol Ther. 2022;55:508-509.
    PubMed    


  351. PARROT L, Dong C, Carbonnel F, Meyer A, et al
    Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Aliment Pharmacol Ther. 2022;55:380-388.
    PubMed     Abstract available


    January 2022
  352. THOMSEN SB, Ungaro RC, Allin KH, Elmahdi R, et al
    Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
    Aliment Pharmacol Ther. 2022 Jan 25. doi: 10.1111/apt.16777.
    PubMed     Abstract available


  353. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Jan 10. doi: 10.1111/apt.16753.
    PubMed     Abstract available


  354. VEISMAN I, Ben-Horin S
    Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients.
    Aliment Pharmacol Ther. 2022;55:131-132.
    PubMed    


  355. LAHARIE D, Riviere P
    Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:129-130.
    PubMed    


  356. CARBONNEL F, Meyer A
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.
    Aliment Pharmacol Ther. 2022;55:251-252.
    PubMed    


  357. GOREN I, Yanai H
    Editorial: risk of loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease-the longer the less?
    Aliment Pharmacol Ther. 2022;55:244-245.
    PubMed    


  358. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:253-254.
    PubMed    


  359. VASUDEVAN A, van Langenberg DR
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy.
    Aliment Pharmacol Ther. 2022;55:108-109.
    PubMed    


  360. BURISCH J, Langholz E, Munkholm P
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:110-111.
    PubMed    


  361. KHAN N, Patel D, Trivedi C, Pernes T, et al
    The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients.
    Aliment Pharmacol Ther. 2022;55:64-72.
    PubMed     Abstract available


  362. BURISCH J, Lophaven S, Langholz E, Munkholm P, et al
    The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017.
    Aliment Pharmacol Ther. 2022;55:73-82.
    PubMed     Abstract available


  363. REZAZADEH ARDABILI A, Mujagic Z, Jonkers DMAE, Pierik MJ, et al
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring.
    Aliment Pharmacol Ther. 2022;55:260-261.
    PubMed    


  364. SCHULTHEISS JPD, Mahmoud R, Fidder HH, Oldenburg B, et al
    Editorial: risk of loss of response to anti TNFalpha in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:246.
    PubMed    


  365. KHAN N, Yang YX
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:262.
    PubMed    


  366. MA C, MacDonald JK, Nguyen TM, Chang J, et al
    Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
    Aliment Pharmacol Ther. 2022;55:178-190.
    PubMed     Abstract available


    December 2021
  367. WANG J, Goren I, Yang B, Lin S, et al
    The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Dec 21. doi: 10.1111/apt.16741.
    PubMed     Abstract available


  368. FLANAGAN E, Prentice R, Wright EK, Gibson PR, et al
    Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16739.
    PubMed     Abstract available


  369. FORSS A, Clements M, Bergman D, Roelstraete B, et al
    A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16735.
    PubMed     Abstract available


  370. HADI Y, Dulai PS, Kupec J, Mohy-Ud-Din N, et al
    Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16730.
    PubMed     Abstract available


  371. CASEY K, Lopes EW, Niccum B, Burke K, et al
    Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts.
    Aliment Pharmacol Ther. 2021 Dec 8. doi: 10.1111/apt.16731.
    PubMed     Abstract available


  372. MESERVE J, Singh S
    Editorial: risk of pneumonia in IBD-reading between the lines!
    Aliment Pharmacol Ther. 2021;54.
    PubMed    


  373. HAMDEH S, Micic D, Hanauer S
    Review article: drug-induced small bowel injury.
    Aliment Pharmacol Ther. 2021;54.
    PubMed     Abstract available


  374. SANDBORN WJ, Lawendy N, Danese S, Su C, et al
    Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
    Aliment Pharmacol Ther. 2021 Dec 1. doi: 10.1111/apt.16712.
    PubMed     Abstract available


    November 2021
  375. ZHAO M, Feng R, Ben-Horin S, Zhuang X, et al
    Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations.
    Aliment Pharmacol Ther. 2021 Nov 24. doi: 10.1111/apt.16703.
    PubMed     Abstract available


  376. RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
    Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
    PubMed     Abstract available


  377. CHAO K, Huang Y, Zhu X, Tang J, et al
    Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1124-1133.
    PubMed     Abstract available


    October 2021
  378. BURISCH J, Lophaven S, Munkholm P, Langholz E, et al
    Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort.
    Aliment Pharmacol Ther. 2021 Oct 29. doi: 10.1111/apt.16677.
    PubMed     Abstract available


  379. BEZZIO C, Armuzzi A, Furfaro F, Ardizzone S, et al
    Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Aliment Pharmacol Ther. 2021 Oct 25. doi: 10.1111/apt.16663.
    PubMed     Abstract available


  380. PASVOL TJ, Bloom S, Segal AW, Rait G, et al
    Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study.
    Aliment Pharmacol Ther. 2021 Oct 18. doi: 10.1111/apt.16647.
    PubMed     Abstract available


  381. RUBIN DT, Modesto I, Vermeire S, Danese S, et al
    Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16619.
    PubMed     Abstract available


  382. FEAGAN BG, Khanna R, Sandborn WJ, Vermeire S, et al
    Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
    Aliment Pharmacol Ther. 2021 Oct 6. doi: 10.1111/apt.16626.
    PubMed     Abstract available


  383. TAKENAKA K, Kawamoto A, Ohtsuka K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:1087.
    PubMed    


  384. RAKOWSKY S, Cheifetz AS, Papamichael K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1085-1086.
    PubMed    


  385. JOLVING LR, Anru PL, Nielsen J, Friedman S, et al
    The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines.
    Aliment Pharmacol Ther. 2021;54:1061-1069.
    PubMed     Abstract available


  386. SAINZ E, Zabana Y, Miguel I, Fernandez-Clotet A, et al
    Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
    Aliment Pharmacol Ther. 2021;54:1041-1051.
    PubMed     Abstract available


  387. TAKENAKA K, Kawamoto A, Hibiya S, Suzuki K, et al
    Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1052-1060.
    PubMed     Abstract available


    September 2021
  388. MULES TC, Swaminathan A, Hirschfeld E, Borichevsky G, et al
    The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.
    Aliment Pharmacol Ther. 2021 Sep 29. doi: 10.1111/apt.16616.
    PubMed     Abstract available


  389. SCHULTHEISS JPD, Mahmoud R, Louwers JM, van der Kaaij MT, et al
    Loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16605.
    PubMed     Abstract available


  390. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16609.
    PubMed     Abstract available


  391. DOHERTY J, Fennessy S, Stack R, O' Morain N, et al
    Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16590.
    PubMed     Abstract available


  392. SAITTA D, Garg M
    Letter: missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease-still significant room for improvement.
    Aliment Pharmacol Ther. 2021;54:734-735.
    PubMed    


  393. BLESL A, Hogenauer C, Borenich A, Berghold A, et al
    Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:720-721.
    PubMed    


  394. BLESL A, Binder L, Hogenauer C, Wenzl H, et al
    Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
    Aliment Pharmacol Ther. 2021;54:667-677.
    PubMed     Abstract available


  395. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
    Aliment Pharmacol Ther. 2021;54:848-849.
    PubMed    


  396. VEYRARD P, Nancey S, Roblin X
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
    Aliment Pharmacol Ther. 2021;54:843-844.
    PubMed    


  397. BERNSTEIN CN, Tennakoon A, Singh H, Targownik L, et al
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:845.
    PubMed    


  398. HAYDEK JP, Scott FI
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
    Aliment Pharmacol Ther. 2021;54:846-847.
    PubMed    


  399. PIERRE N, Salee C, Vieujean S, Bequet E, et al
    Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology.
    Aliment Pharmacol Ther. 2021;54:779-791.
    PubMed     Abstract available


  400. BERNSTEIN CN, Tenakoon A, Singh H, Targownik LE, et al
    Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.
    Aliment Pharmacol Ther. 2021;54:814-832.
    PubMed     Abstract available


    August 2021
  401. SLEUTJES JAM, Roeters van Lennep JE, Boersma E, Menchen LA, et al
    Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
    Aliment Pharmacol Ther. 2021 Aug 28. doi: 10.1111/apt.16580.
    PubMed     Abstract available


  402. HONAP S, Pavlidis P, Irving PM
    Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;54:341-342.
    PubMed    


  403. BIEMANS VBC, Straatmijer T, Hoentjen F, Pierik MJ, et al
    Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:534-535.
    PubMed    


  404. LO SW, Connell W, Kamm MA, Lust M, et al
    Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
    Aliment Pharmacol Ther. 2021;54:532-533.
    PubMed    


  405. ROBLIN X, Nancey S, Paul S
    Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:538-539.
    PubMed    


  406. FRIEDMAN AB, Gibson PR
    Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:510.
    PubMed    


  407. HORJUS-TALABUR HORJE CS, van Bodegraven AA
    Editorial: assessment of inflammatory bowel disease-a picture is worth a thousand words.
    Aliment Pharmacol Ther. 2021;54:508-509.
    PubMed    


  408. TSOI AH, Murugasu A, Garg M
    Letter: assessment of histological disease activity in Crohn's disease clinical trials-a step in the right direction, but further optimisation needed.
    Aliment Pharmacol Ther. 2021;54:541-542.
    PubMed    


  409. DEMARZO MG, Bodini G, Giuliana E, Zentilin P, et al
    Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
    Aliment Pharmacol Ther. 2021;54:536-537.
    PubMed    


  410. MATTOO VY, Basnayake C, Connell WR, Ding N, et al
    Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:249-266.
    PubMed     Abstract available


    July 2021
  411. LAMBERT K, Pappas D, Miglioretto C, Javadpour A, et al
    Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jul 29. doi: 10.1111/apt.16549.
    PubMed     Abstract available


  412. FUMERY M, Filippi J, Abitbol V, Biron A, et al
    Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
    Aliment Pharmacol Ther. 2021 Jul 23. doi: 10.1111/apt.16544.
    PubMed     Abstract available


  413. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
    Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
    PubMed     Abstract available


  414. MCGING JJ, Radford SJ, Francis ST, Serres S, et al
    Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
    Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
    PubMed     Abstract available


  415. LUBER RP, O'Neill R, Singh S, Sharma E, et al
    An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
    PubMed     Abstract available


  416. ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
    Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
    Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
    PubMed     Abstract available


  417. OSENI E, Sultan K
    Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
    Aliment Pharmacol Ther. 2021;54:92-93.
    PubMed    


  418. JORDI SBU, Misselwitz B, Begre S
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:82-83.
    PubMed    


  419. KNOWLES SR, Mikocka-Walus A
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;54:80-81.
    PubMed    


  420. FAN D, Gearry RB
    Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
    Aliment Pharmacol Ther. 2021;54:208-209.
    PubMed    


  421. TASSONE D, Singh S, Sheng Ding N
    Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Aliment Pharmacol Ther. 2021;54:206-207.
    PubMed    


  422. MEYER A, Semenzato L, Zureik M, Weill A, et al
    Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Aliment Pharmacol Ther. 2021;54:160-166.
    PubMed     Abstract available


  423. CASANOVA MJ, Chaparro M, Gisbert JP
    Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:86-87.
    PubMed    


  424. PUGLIESE D, Armuzzi A
    Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
    Aliment Pharmacol Ther. 2021;54:84-85.
    PubMed    


  425. WEISSHOF R, Chowers Y, Kurnik D
    Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
    Aliment Pharmacol Ther. 2021;54:88-89.
    PubMed    


    June 2021
  426. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
    The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
    PubMed     Abstract available


  427. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
    PubMed     Abstract available


  428. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
    Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
    PubMed     Abstract available


  429. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
    Comorbidity before and after a diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
    PubMed     Abstract available


  430. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
    Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
    PubMed     Abstract available


  431. KO Y, Paramsothy S, Yau Y, Leong RW, et al
    Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
    PubMed     Abstract available


  432. VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
    Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
    PubMed     Abstract available


  433. FAIRBRASS KM, Gracie DJ, Ford AC
    Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
    PubMed     Abstract available


  434. LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
    Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2021;53:1236-1240.
    PubMed    


  435. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1234-1235.
    PubMed    


  436. VERNON-ROBERTS A, Day AS
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
    Aliment Pharmacol Ther. 2021;53:1232-1233.
    PubMed    


  437. TANNOURY J, Amiot A
    Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1323.
    PubMed    


  438. TURBAYNE AKB, Ward MG
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
    Aliment Pharmacol Ther. 2021;53:1317-1318.
    PubMed    


  439. ROBLIN X, Nancey S, Paul S
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1319-1320.
    PubMed    


  440. LIMDI JK
    Editorial: determining disability in IBD - 'See(k) and you shall find'.
    Aliment Pharmacol Ther. 2021;53:1321-1322.
    PubMed    


  441. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
    Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Aliment Pharmacol Ther. 2021;53:1289-1299.
    PubMed     Abstract available


    May 2021
  442. JORDI SBU, Botte F, Lang BM, Greuter T, et al
    Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
    PubMed     Abstract available


  443. CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
    Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
    Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
    PubMed     Abstract available


  444. SRINIVASAN A, Haifer C, Thin L
    Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
    Aliment Pharmacol Ther. 2021;53:1038-1039.
    PubMed    


  445. WILSON A, Kim RB
    Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
    Aliment Pharmacol Ther. 2021;53:1055-1056.
    PubMed    


  446. DEMARZO MG, Bodini G, Vanello M, Martini M, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
    Aliment Pharmacol Ther. 2021;53:1044-1045.
    PubMed    


  447. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1046-1047.
    PubMed    


  448. MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
    Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2021;53:1021-1029.
    PubMed     Abstract available


  449. SEDANO R, Ma C, Jairath V
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1149-1150.
    PubMed    


  450. LAUBE R, Selinger CP
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
    Aliment Pharmacol Ther. 2021;53:1147-1148.
    PubMed    


  451. TANNOURY J, Nachury M, Martins C, Serrero M, et al
    Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
    Aliment Pharmacol Ther. 2021;53:1098-1107.
    PubMed     Abstract available


  452. TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
    Review article: investigation and management of internal fistulae in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:1064-1079.
    PubMed     Abstract available


    April 2021
  453. DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
    One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
    PubMed     Abstract available


  454. TOURNIER Q, Paul S, Williet N, Berger AE, et al
    Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
    PubMed     Abstract available


  455. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
    Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
    PubMed     Abstract available


  456. VAN DER HAVE M, Maljaars J
    Editorial: opioids in inflammatory bowel disease-primum non nocere.
    Aliment Pharmacol Ther. 2021;53:844-845.
    PubMed    


  457. RHUDY C, Perry CL, Barrett TA
    Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:846.
    PubMed    


  458. JANGI S, Yoon H, Dulai P, Valasek M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
    Aliment Pharmacol Ther. 2021;53:957-958.
    PubMed    


  459. MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:955-956.
    PubMed    


  460. PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
    Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
    Aliment Pharmacol Ther. 2021;53:953-954.
    PubMed    


  461. LUBELL JM
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
    Aliment Pharmacol Ther. 2021;53:851-852.
    PubMed    


  462. BAGER P, Hvas C, Rud C, Dahlerup J, et al
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:853-854.
    PubMed    


  463. LIM G, Kassam Z, Seow CH
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
    Aliment Pharmacol Ther. 2021;53:855-856.
    PubMed    


  464. TURSI A, Mocci G, Picchio M, Elisei W, et al
    Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:859-860.
    PubMed    


  465. LAHARIE D, Riviere P
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:857-858.
    PubMed    


  466. ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
    An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
    Aliment Pharmacol Ther. 2021;53:784-793.
    PubMed     Abstract available


  467. ABUSHAMMA S, Deepak P
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
    Aliment Pharmacol Ther. 2021;53:946-947.
    PubMed    


  468. JAIRATH V, Almradi A, Pai RK, Ma C, et al
    Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:952.
    PubMed    


  469. TANDON P, Narula N
    Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
    Aliment Pharmacol Ther. 2021;53:950-951.
    PubMed    


  470. GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:948-949.
    PubMed    


  471. GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
    Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:873-886.
    PubMed     Abstract available


    March 2021
  472. WORLEY G, Faiz O
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:661-662.
    PubMed    


  473. BODGER K
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
    Aliment Pharmacol Ther. 2021;53:660.
    PubMed    


  474. LAHARIE D
    Editorial: is enteral nutrition back in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;53:745-746.
    PubMed    


  475. AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
    Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Aliment Pharmacol Ther. 2021;53:766-767.
    PubMed    


  476. SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
    Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:747-748.
    PubMed    


  477. O'MORAIN N, Coe C, Mallon P, Twomey P, et al
    Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
    Aliment Pharmacol Ther. 2021;53:674-675.
    PubMed    


  478. PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
    Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
    Aliment Pharmacol Ther. 2021;53:764-765.
    PubMed    


  479. TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
    Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
    PubMed     Abstract available


  480. KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
    Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
    PubMed     Abstract available


  481. MANTZARIS GJ, Bamias G
    Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
    Aliment Pharmacol Ther. 2021;53:749-750.
    PubMed    


  482. ROBLIN X, Paul S, Nancey S
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
    Aliment Pharmacol Ther. 2021;53:640-641.
    PubMed    


  483. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
    Aliment Pharmacol Ther. 2021;53:642-643.
    PubMed    


  484. MCCURDY J, Boet S, Rosenfeld G
    Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
    Aliment Pharmacol Ther. 2021;53:667-668.
    PubMed    


  485. LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
    Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:577-586.
    PubMed     Abstract available


  486. LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
    Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:587-597.
    PubMed     Abstract available


    February 2021
  487. FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
    Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
    Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
    PubMed     Abstract available


  488. JAHRAUS CD
    Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;53:454-455.
    PubMed    


  489. AXELRAD JE
    Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
    Aliment Pharmacol Ther. 2021;53:563-564.
    PubMed    


  490. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:445-446.
    PubMed    


  491. WILS P, Pariente B
    Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2021;53:452-453.
    PubMed    


  492. SEOW CH, Ma C
    Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
    Aliment Pharmacol Ther. 2021;53:450-451.
    PubMed    


  493. TOWNSEND T, Subramanian S
    Editorial: vedolizumab in inflammatory bowel diseases-less is more?
    Aliment Pharmacol Ther. 2021;53:443-444.
    PubMed    


  494. MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
    Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2021;53:374-382.
    PubMed     Abstract available


    January 2021
  495. RHUDY C, Perry CL, Singleton M, Talbert J, et al
    Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
    PubMed     Abstract available


  496. SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
    Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
    PubMed     Abstract available


  497. CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:337-338.
    PubMed    


  498. MAHMOUD R, Itzkowitz SH
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
    Aliment Pharmacol Ther. 2021;53:335-336.
    PubMed    


  499. LORD A, Radford-Smith G
    Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:368-369.
    PubMed    


  500. RIMOLA J, Panes J, Ordas I
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;53:207-208.
    PubMed    


  501. DEBNATH P, Rathi P
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:205-206.
    PubMed    


  502. MURRAY CD
    Editorial: fatigue-difficult to assess and difficult to treat.
    Aliment Pharmacol Ther. 2021;53:339.
    PubMed    


  503. LEBLANC JF, Hart AL
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
    Aliment Pharmacol Ther. 2021;53:342-343.
    PubMed    


  504. TOWNSEND T, Subramanian S
    Letter: propensity score-handle with care. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:362-363.
    PubMed    


  505. MACALUSO FS, Orlando A
    Letter: propensity score-handle with care.
    Aliment Pharmacol Ther. 2021;53:360-361.
    PubMed    


  506. CARBERY I, Selinger CP
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
    Aliment Pharmacol Ther. 2021;53:346-347.
    PubMed    


  507. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:344-345.
    PubMed    


  508. SCHREINER P, von Kanel R, Misselwitz B
    Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:340-341.
    PubMed    


  509. BERTANI L, Pugliese D, Trico D, Costa F, et al
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:348-349.
    PubMed    


  510. NICE R, Chanchlani N, Green H, Bewshea C, et al
    Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
    Aliment Pharmacol Ther. 2021;53:128-137.
    PubMed     Abstract available


  511. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
    Aliment Pharmacol Ther. 2021;53:265-272.
    PubMed     Abstract available


  512. BERTANI L, Trico D, Pugliese D, Privitera G, et al
    Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
    Aliment Pharmacol Ther. 2021;53:273-280.
    PubMed     Abstract available


  513. FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
    Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
    Aliment Pharmacol Ther. 2021;53:22-32.
    PubMed     Abstract available


  514. PAI RK, Pai RK, Brown I, Choi WT, et al
    The significance of histological activity measurements in immune checkpoint inhibitor colitis.
    Aliment Pharmacol Ther. 2021;53:150-159.
    PubMed     Abstract available


  515. UNGARO RC, Hu L, Ji J, Nayar S, et al
    Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:281-290.
    PubMed     Abstract available


  516. KING D, Coupland B, Dosanjh A, Cole A, et al
    The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
    Aliment Pharmacol Ther. 2021;53:114-127.
    PubMed     Abstract available


    December 2020
  517. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
    PubMed     Abstract available


  518. YE L, Chapman TP, Wen Z, Lin L, et al
    Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
    PubMed     Abstract available


  519. PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
    Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
    Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
    PubMed     Abstract available


  520. WILS P, Seksik P, Stefanescu C, Nancey S, et al
    Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
    PubMed     Abstract available


  521. LO CH, Khalili H, Lochhead P, Song M, et al
    Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
    PubMed     Abstract available


  522. WORLEY G, Almoudaris A, Bassett P, Segal J, et al
    Colectomy rates for ulcerative colitis in England 2003-2016.
    Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
    PubMed     Abstract available


  523. REUKEN PA, Wust M, Loffler B, Bauer M, et al
    Letter: SARS-CoV-2-induced gastrointestinal inflammation.
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


    November 2020
  524. DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
    Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
    PubMed     Abstract available


  525. BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
    Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
    Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
    PubMed     Abstract available


  526. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
    PubMed     Abstract available


  527. HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
    5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
    PubMed     Abstract available


  528. SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
    Fatigue in inflammatory bowel disease and its impact on daily activities.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
    PubMed     Abstract available


  529. GORDON C, Chee D, Hamilton B, Heerasing NM, et al
    Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
    PubMed     Abstract available


  530. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2020;52:1480-1490.
    PubMed     Abstract available


  531. NICOLAIDES S, Vasudevan A, van Langenberg D
    Letter: rationalising aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:1619-1620.
    PubMed    


  532. MA C, Singh S, Heatherington J, Panaccione R, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
    Aliment Pharmacol Ther. 2020;52:1615-1616.
    PubMed    


  533. ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1617-1618.
    PubMed    


  534. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1621.
    PubMed    


  535. NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
    Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
    Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
    PubMed     Abstract available


  536. VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
    Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1529-1530.
    PubMed    


  537. ZULFIQAR M, Deepak P
    Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1531-1532.
    PubMed    


  538. FRASER AG
    Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
    Aliment Pharmacol Ther. 2020;52:1527-1528.
    PubMed    


  539. FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
    Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Aliment Pharmacol Ther. 2020;52:1551-1562.
    PubMed     Abstract available


  540. TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
    Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1491-1502.
    PubMed     Abstract available


  541. RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
    Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1563-1573.
    PubMed     Abstract available


    October 2020
  542. BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
    NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
    Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
    PubMed     Abstract available


  543. PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
    Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
    PubMed     Abstract available


  544. AMIOT A, Salameh R
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1252.
    PubMed    


  545. FABIAN A, Bor R, Farkas K, Szepes Z, et al
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
    Aliment Pharmacol Ther. 2020;52:1251.
    PubMed    


  546. PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
    Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
    Aliment Pharmacol Ther. 2020;52:1422-1423.
    PubMed    


  547. BRITTON E, Richardson P, Mian I, Conley T, et al
    Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
    Aliment Pharmacol Ther. 2020;52:1414-1415.
    PubMed    


  548. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1255-1256.
    PubMed    


  549. LIU K, Cai F, Huang J
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Aliment Pharmacol Ther. 2020;52:1253-1254.
    PubMed    


  550. LAHARIE D, Riviere P
    Editorial: biologics in the therapy of Crohn's disease-the fog clears.
    Aliment Pharmacol Ther. 2020;52:1214-1215.
    PubMed    


  551. MERTZ NORGARD B, Friedman S
    Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1411.
    PubMed    


  552. BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
    Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
    Aliment Pharmacol Ther. 2020;52:1104-1116.
    PubMed     Abstract available


  553. TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
    Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1341-1352.
    PubMed     Abstract available


    September 2020
  554. BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
    Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
    Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
    PubMed     Abstract available


  555. JANGI S, Yoon H, Dulai PS, Valasek M, et al
    Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
    Aliment Pharmacol Ther. 2020;52:1008-1016.
    PubMed     Abstract available


  556. CHEE D, Goodhand JR, Ahmad T
    Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
    Aliment Pharmacol Ther. 2020;52:1076-1077.
    PubMed    


  557. APPLETON L, Day AS
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:1080-1081.
    PubMed    


  558. ROBLIN X, Le Roy B, Paul S
    Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
    Aliment Pharmacol Ther. 2020;52:1078-1079.
    PubMed    


  559. BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1082.
    PubMed    


  560. KOPYLOV U
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Aliment Pharmacol Ther. 2020;52:907.
    PubMed    


  561. DESAI D, Abraham P
    Letter: monitoring interval for thiopurine therapy - a comment.
    Aliment Pharmacol Ther. 2020;52:910.
    PubMed    


  562. HUDSON J, Herfarth HH, Barnes EL
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:906.
    PubMed    


  563. JONES K, Baker K, Speight RA, Thompson NP, et al
    Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:964-975.
    PubMed     Abstract available


  564. BROMS G, Kieler H, Ekbom A, Gissler M, et al
    Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
    Aliment Pharmacol Ther. 2020;52:843-854.
    PubMed     Abstract available


  565. IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
    Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2020;52:1017-1030.
    PubMed     Abstract available


    August 2020
  566. KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
    Letter: IBD nurse-a pivotal role in the time of the pandemic.
    Aliment Pharmacol Ther. 2020;52:745.
    PubMed    


  567. BERTANI L, Antonioli L, Blandizzi C
    Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
    Aliment Pharmacol Ther. 2020;52:751-752.
    PubMed    


  568. AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
    Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:746-747.
    PubMed    


  569. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:753-754.
    PubMed    


  570. MARSH A, Radford-Smith G
    Editorial: obesity management and IBD-weight loss reduces IBD risk.
    Aliment Pharmacol Ther. 2020;52:731-732.
    PubMed    


  571. KANG B, Kim TJ, Choi J, Baek SY, et al
    Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Aliment Pharmacol Ther. 2020;52:459-470.
    PubMed     Abstract available


  572. WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
    Quality improvement project identifies factors associated with delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:471-480.
    PubMed     Abstract available


  573. BOHM M, Xu R, Zhang Y, Varma S, et al
    Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:669-681.
    PubMed     Abstract available


  574. SEGAL JP, Smith PJ
    Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:733-734.
    PubMed    


    July 2020
  575. BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
    Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Aliment Pharmacol Ther. 2020;52:123-134.
    PubMed     Abstract available


  576. KABIR M, Fofaria R, Arebi N, Bassett P, et al
    Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
    Aliment Pharmacol Ther. 2020;52:5-19.
    PubMed     Abstract available


  577. KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
    Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Aliment Pharmacol Ther. 2020;52:135-142.
    PubMed     Abstract available


  578. KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
    Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:311-318.
    PubMed     Abstract available


  579. THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
    Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:247-266.
    PubMed     Abstract available


  580. DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
    Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
    Aliment Pharmacol Ther. 2020;52:303-310.
    PubMed     Abstract available


  581. BERTANI L, Fornai M, Fornili M, Antonioli L, et al
    Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:284-291.
    PubMed     Abstract available


    June 2020
  582. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1031-1038.
    PubMed     Abstract available


  583. LU C, Baraty B, Lee Robertson H, Filyk A, et al
    Systematic review: medical therapy for fibrostenosing Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1233-1246.
    PubMed     Abstract available


  584. SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
    A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1342-1352.
    PubMed     Abstract available


  585. PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
    Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
    Aliment Pharmacol Ther. 2020;51:1268-1285.
    PubMed     Abstract available


  586. CZAJA AJ
    Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
    Aliment Pharmacol Ther. 2020;51:1286-1304.
    PubMed     Abstract available


    May 2020
  587. UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
    Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:831-842.
    PubMed     Abstract available


  588. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
    Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
    Aliment Pharmacol Ther. 2020;51:899-908.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.